Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Up 27.1% in October

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 123,200 shares, an increase of 27.1% from the October 15th total of 96,900 shares. Based on an average daily volume of 120,900 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.7% of the company’s stock are short sold.

Institutional Investors Weigh In On Inspira Technologies Oxy B.H.N.

A hedge fund recently bought a new stake in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC bought a new position in shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 24,497 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned approximately 0.19% of Inspira Technologies Oxy B.H.N. at the end of the most recent quarter. 12.72% of the stock is currently owned by institutional investors and hedge funds.

Inspira Technologies Oxy B.H.N. Price Performance

Shares of IINN stock opened at $1.22 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.13 and a current ratio of 2.23. Inspira Technologies Oxy B.H.N. has a 52 week low of $0.76 and a 52 week high of $2.49. The company’s 50 day moving average price is $1.31 and its two-hundred day moving average price is $1.45.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.